WHO adds emicizumab and recombinant clotting factors to its Essential Medicines List, a major win for global bleeding disorders care and access.

FDA expands VONVENDI approval to include prophylaxis for adults with von Willebrand disease and pediatric on-demand use, advancing care across all VWD types.

NBDF advocates for bleeding disorders care and coverage—BDC 2025 highlights, federal policy updates, Medicaid privacy, insurance reforms, and state actions.

A New Class of Cellular Medicines: The First Engineered B Cell Medicine to Enter Clinical Trials for Hemophilia B

Explore insights from BDC 2025 on gene therapy, new treatments, and the concept of a hemophilia-free mind. Learn how innovation and community voices shape the future of care.

Learn how multidisciplinary teams can improve bleeding disorders care through research, evidence-based practice, and quality improvement, shared at BDC 2025.

See the energy, inspiration, and celebration that closed out the final day of BDC 2025 in our photo highlights.

From inspiring sessions to fun-filled workshops and community gatherings, see how Friday filled every corner of BDC 2025 with energy and smiles

At BDC 2025, NBDF hosted sessions and networking hours that honored identity, built connections, and reminded attendees that no one walks alone.

A hands-on BDC 2025 workshop used craft supplies to make the clotting process easy to see and understand.